Can-Fite Biopharma Ltd ADR (CANF)

$3.39 +0.03 (0.89%)
Market Cap 2.20M
Revenue (ttm) 410,000.00
Net Income (ttm) -9.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,397.56%
Debt to Equity Ratio 0.00
Volume 29,300
Avg Vol 1,415,954
Day's Range N/A - N/A
Shares Out 655,000.00
Stochastic %K 43%
Beta 1.09
Analysts Sell
Price Target $4.50

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 924 1114
Fax: 972 3 924 9378
Address:
26 Ben Gurion Street, Ramat Gan, Israel
MarketMasterMind
MarketMasterMind May. 13 at 3:02 PM
$TDIC | $CANF 🤑Ⓜ️
0 · Reply
DARKP00L
DARKP00L May. 13 at 12:00 PM
$CANF 07:06 on May. 13 2026 Can-Fite BioPharma Plans To Advance Pancreatic Cancer Program Into Phase 2b Study Evaluating Namodenoson In Combination With Immunotherapy In Patients With Advanced Pancreatic Cancer #tradeideas
0 · Reply
GeeJoon
GeeJoon May. 13 at 11:32 AM
$CANF well, partnership with BIG PHARMA!!!
0 · Reply
DARKP00L
DARKP00L May. 13 at 11:10 AM
$CANF 07:06 on May. 13 2026 Can-Fite BioPharma Plans To Advance Pancreatic Cancer Program Into Phase 2b Study Evaluating Namodenoson In Combination With Immunotherapy In Patients With Advanced Pancreatic Cancer #tradeideas
0 · Reply
DekmarTrades
DekmarTrades May. 13 at 11:03 AM
$CANF Best PR I see at 7am EST!
0 · Reply
DekmarTrades
DekmarTrades May. 13 at 11:00 AM
$CANF High Alert for a $4 Break!
0 · Reply
GeeJoon
GeeJoon May. 12 at 12:14 PM
$CANF only after 6 months, H.C. Wainwright cut price target from $50 to $5
0 · Reply
GeeJoon
GeeJoon May. 10 at 11:24 PM
$CANF now only $0.175 pre rs, $100 is only $5 pre rs.
0 · Reply
CoachHendo
CoachHendo May. 10 at 5:32 PM
$CANF $SLNH 2 for 2!
0 · Reply
GeeJoon
GeeJoon May. 8 at 7:42 AM
$CANF Jews are pumping this shit...
0 · Reply
Latest News on CANF
Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

2026-05-13T13:49:05.000Z - 1 hour ago

Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Wed, 13 May 2026 07:00:00 -0400 - 4 hours ago

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

2026-05-12T10:49:37.000Z - 1 day ago

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Thu, 30 Apr 2026 08:31:00 -0400 - 13 days ago

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Can-Fite BioPharma files to sell 3.29M ordinary shares for holders

2026-03-31T10:16:55.000Z - 6 weeks ago

Can-Fite BioPharma files to sell 3.29M ordinary shares for holders

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

2026-03-30T22:03:00.000Z - 6 weeks ago

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

Can-Fite BioPharma completes enrollment in Piclidenoson study

2026-03-30T11:37:18.000Z - 6 weeks ago

Can-Fite BioPharma completes enrollment in Piclidenoson study

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Mon, 30 Mar 2026 07:20:00 -0400 - 6 weeks ago

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Thu, 26 Mar 2026 09:27:00 -0400 - 6 weeks ago

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

2026-03-17T13:28:03.000Z - 2 months ago

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

Can-Fite BioPharma announces Israeli patent allowance for namodenoson

2026-03-17T11:50:14.000Z - 2 months ago

Can-Fite BioPharma announces Israeli patent allowance for namodenoson

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

Tue, 17 Mar 2026 07:47:00 -0400 - 2 months ago

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

2026-03-04T16:50:16.000Z - 2 months ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Wed, 04 Mar 2026 10:07:28 -0500 - 2 months ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

2026-03-04T12:34:33.000Z - 2 months ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study

2026-03-04T12:09:03.000Z - 2 months ago

Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Wed, 04 Mar 2026 07:00:00 -0500 - 2 months ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

2026-02-17T12:36:34.000Z - 3 months ago

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson

2026-02-17T12:15:35.000Z - 3 months ago

Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

2026-02-09T12:30:05.000Z - 3 months ago

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

Can-Fite BioPharma receives Canadian patent allowance for namodenoson

2026-02-09T12:15:27.000Z - 3 months ago

Can-Fite BioPharma receives Canadian patent allowance for namodenoson

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

2026-02-05T12:33:49.000Z - 3 months ago

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

Can-Fite announces patient with liver cirrhosis treated with Namodenoson

2026-02-05T12:17:59.000Z - 3 months ago

Can-Fite announces patient with liver cirrhosis treated with Namodenoson

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

2026-01-20T12:37:35.000Z - 4 months ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

Can-Fite completes patient enrollment in Phase 2a study of Namodenoson

2026-01-20T12:10:21.000Z - 4 months ago

Can-Fite completes patient enrollment in Phase 2a study of Namodenoson

Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital

2025-12-24T15:50:08.000Z - 4 months ago

Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

2025-12-23T22:55:20.000Z - 5 months ago

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

2025-12-23T22:25:23.000Z - 5 months ago

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change

2025-12-23T21:50:11.000Z - 5 months ago

Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Tue, 23 Dec 2025 16:46:00 -0500 - 5 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

2025-12-17T13:30:15.000Z - 5 months ago

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

2025-12-16T15:29:50.000Z - 5 months ago

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

Can-Fite BioPharma provides clinical, financial update

2025-12-16T14:25:37.000Z - 5 months ago

Can-Fite BioPharma provides clinical, financial update

Can-Fite Provides Update on Clinical and Financial Status

Tue, 16 Dec 2025 09:19:00 -0500 - 5 months ago

Can-Fite Provides Update on Clinical and Financial Status

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

2025-11-24T12:30:24.000Z - 6 months ago

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

Can-Fite BioPharma to participate in BioFIT 2025

2025-11-24T12:15:09.000Z - 6 months ago

Can-Fite BioPharma to participate in BioFIT 2025

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

2025-11-20T12:42:31.000Z - 6 months ago

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602

2025-11-20T12:05:46.000Z - 6 months ago

Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Thu, 20 Nov 2025 07:00:00 -0500 - 6 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

2025-11-18T20:00:37.000Z - 6 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and Price Target | CANF Stock News

Why Is Can-Fite BioPharma Stock (CANF) Up Today?

2025-11-18T14:19:26.000Z - 6 months ago

Why Is Can-Fite BioPharma Stock (CANF) Up Today?

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

2025-11-18T12:30:20.000Z - 6 months ago

Can-Fite BioPharma's (CANF) Namodenoson Shows Promising Long-Term Survival

Can-Fite announces 9-year survival with complete cure with Namodenoson

2025-11-18T12:16:46.000Z - 6 months ago

Can-Fite announces 9-year survival with complete cure with Namodenoson

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

2025-11-04T12:01:46.000Z - 6 months ago

CANF: HC Wainwright Initiates Buy Rating with $2.50 Price Target | CANF Stock News

Can-Fite BioPharma assumed with a Buy at H.C. Wainwright

2025-11-04T11:16:11.000Z - 6 months ago

Can-Fite BioPharma assumed with a Buy at H.C. Wainwright

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

2025-09-16T12:32:06.000Z - 8 months ago

CANF: Analyst Jason Kolbert Maintains Buy Rating and $11 PT | CANF Stock News

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

2025-09-15T12:40:09.000Z - 8 months ago

Can-Fite BioPharma (CANF) Reports Breakthrough in Liver Cirrhosis Treatment

Can-Fite BioPharma announces new findings for Namodenoson

2025-09-15T11:05:28.000Z - 8 months ago

Can-Fite BioPharma announces new findings for Namodenoson

Can-Fite BioPharma reports 1H EPS 0c vs. 0c last year

2025-08-28T12:55:30.000Z - 9 months ago

Can-Fite BioPharma reports 1H EPS 0c vs. 0c last year

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Thu, 28 Aug 2025 08:47:00 -0400 - 9 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Wed, 30 Jul 2025 07:04:00 -0400 - 10 months ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 12:24 PM EDT - 10 months ago

Can-Fite Announces Up To $15.0 Million Public Offering

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Jul 28, 2025, 7:00 AM EDT - 10 months ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 17, 2025, 8:55 AM EDT - 1 year ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Apr 14, 2025, 2:28 PM EDT - 1 year ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 20, 2025, 9:45 AM EDT - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mar 3, 2025, 6:00 AM EST - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 10, 2025, 7:10 AM EST - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Feb 5, 2025, 7:00 AM EST - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Dec 30, 2024, 7:00 AM EST - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 29, 2024, 8:15 AM EDT - 1 year ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 9, 2024, 9:00 AM EDT - 1 year ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 7:01 PM EDT - 1 year ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 17, 2024, 7:00 AM EDT - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jul 11, 2024, 7:00 AM EDT - 1 year ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 28, 2024, 7:00 AM EDT - 2 years ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 10, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 29, 2024, 7:00 AM EDT - 2 years ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 27, 2024, 7:00 AM EDT - 2 years ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 23, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 13, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 2 years ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 9, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

May 6, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Apr 25, 2024, 7:00 AM EDT - 2 years ago

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Apr 15, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Apr 3, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Apr 1, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV

Can-Fite Reports 2023 Financial Results and Clinical Update

Mar 28, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Reports 2023 Financial Results and Clinical Update

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference

MarketMasterMind
MarketMasterMind May. 13 at 3:02 PM
$TDIC | $CANF 🤑Ⓜ️
0 · Reply
DARKP00L
DARKP00L May. 13 at 12:00 PM
$CANF 07:06 on May. 13 2026 Can-Fite BioPharma Plans To Advance Pancreatic Cancer Program Into Phase 2b Study Evaluating Namodenoson In Combination With Immunotherapy In Patients With Advanced Pancreatic Cancer #tradeideas
0 · Reply
GeeJoon
GeeJoon May. 13 at 11:32 AM
$CANF well, partnership with BIG PHARMA!!!
0 · Reply
DARKP00L
DARKP00L May. 13 at 11:10 AM
$CANF 07:06 on May. 13 2026 Can-Fite BioPharma Plans To Advance Pancreatic Cancer Program Into Phase 2b Study Evaluating Namodenoson In Combination With Immunotherapy In Patients With Advanced Pancreatic Cancer #tradeideas
0 · Reply
DekmarTrades
DekmarTrades May. 13 at 11:03 AM
$CANF Best PR I see at 7am EST!
0 · Reply
DekmarTrades
DekmarTrades May. 13 at 11:00 AM
$CANF High Alert for a $4 Break!
0 · Reply
GeeJoon
GeeJoon May. 12 at 12:14 PM
$CANF only after 6 months, H.C. Wainwright cut price target from $50 to $5
0 · Reply
GeeJoon
GeeJoon May. 10 at 11:24 PM
$CANF now only $0.175 pre rs, $100 is only $5 pre rs.
0 · Reply
CoachHendo
CoachHendo May. 10 at 5:32 PM
$CANF $SLNH 2 for 2!
0 · Reply
GeeJoon
GeeJoon May. 8 at 7:42 AM
$CANF Jews are pumping this shit...
0 · Reply
GeeJoon
GeeJoon May. 8 at 5:42 AM
$CANF
0 · Reply
GeeJoon
GeeJoon May. 7 at 5:46 PM
$CANF let's talk about veterinary drug alone, marketcap should be at least 325m with Vetbiolix's deal, all R&D cost borne by partner, we only have to wait for fruitful result, so fairly sp should be at least 40x from now, $150 for only this pipeline, we'd love to see this company explore more in veterinary partnership, cuz it's much easier and cheaper for the drugs to get approved... https://ir.canfite.com/news-events/press-releases/detail/1096/can-fite-to-advance-new-veterinary-partnership
0 · Reply
MarketMasterMind
MarketMasterMind May. 6 at 1:45 PM
$SSM | $CANF | $AREB | $GDC Ⓜ️
0 · Reply
GeeJoon
GeeJoon May. 6 at 1:09 PM
$CANF
0 · Reply
Tryingtoretire01
Tryingtoretire01 May. 6 at 12:16 PM
$CANF this one is going to get interesting soon
0 · Reply
MarketMasterMind
MarketMasterMind May. 6 at 10:50 AM
$SSM wants back over $10 🤑 $CANF lots of wicks and gaps to be filled to $10+ as well Ⓜ️
0 · Reply
GeeJoon
GeeJoon May. 6 at 10:31 AM
$CANF 3 drugs will be approved soonest... 2027: namodenoson for liver cancer HCC CPB7 2028: piclidenoson for psoriasis 2029: piclidenoson for dogs osteoarthritis
0 · Reply
24DV4NC3D
24DV4NC3D May. 5 at 7:49 PM
$CANF $OWL ⚡️WHAT DID I SAY?!⚡️ ⚠️WARNED 4.30.26 >>>>>>> LISTEN! <<<<<<<
0 · Reply
MarketMasterMind
MarketMasterMind May. 5 at 6:58 PM
$SSM | $CANF send em 🤑Ⓜ️
0 · Reply
GeeJoon
GeeJoon May. 5 at 6:57 PM
$CANF volume keep increasing, wish inst accumulating, Q2 remaining 55 days for psoriasis P3 interim result, piclidenoson has already gone through a P3 named COMFORT in 2022, if this time pivot P3 has consistent data, this drug will be one step close to the market, an FDA approved drug worth at least 500m
0 · Reply
MarketMasterMind
MarketMasterMind May. 5 at 5:13 PM
$SSM low float still adding $OSRH | $CANF | $GDC
0 · Reply
MarketMasterMind
MarketMasterMind May. 5 at 2:31 PM
$VEEE | $GDC | $CANF 🤑Ⓜ️
0 · Reply